165 related articles for article (PubMed ID: 16029590)
21. Therapeutic potential of dendritic cell-based immunization against HBV in transgenic mice.
Jiang WZ; Fan Y; Liu X; Zhang YL; Wen JJ; Hao WL; Qian M
Antiviral Res; 2008 Jan; 77(1):50-5. PubMed ID: 17897731
[TBL] [Abstract][Full Text] [Related]
22. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B.
Lin CL; Tsai SL; Lee TH; Chien RN; Liao SK; Liaw YF
Gut; 2005 Jan; 54(1):152-61. PubMed ID: 15591521
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.
Iwabuchi M; Narita M; Uchiyama T; Iwaya S; Oiwa E; Nishizawa Y; Hashimoto S; Bonehill A; Kasahara N; Takizawa J; Takahashi M
Mol Med Rep; 2015 Aug; 12(2):2443-50. PubMed ID: 25936433
[TBL] [Abstract][Full Text] [Related]
24. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
25. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
26. [Impaired non-viral specific immune function of dendritic cell does not interfere with clearance and cytotoxic T lymphocyte response to HBV or HCV].
Fan CL; Chen HS; Li RB; Wang SX; Cong X; Fei R; Jiang D; Wang Y; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):67-71. PubMed ID: 14980100
[TBL] [Abstract][Full Text] [Related]
27. Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients.
Hao X; Shao Y; Ren X; Liu H; Xu Q; Li H; Zhang P; An X; Ren B
J Cancer Res Clin Oncol; 2002 Sep; 128(9):507-15. PubMed ID: 12242516
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B Virus Surface Antigen Activates Myeloid Dendritic Cells via a Soluble CD14-Dependent Mechanism.
van Montfoort N; van der Aa E; van den Bosch A; Brouwers H; Vanwolleghem T; Janssen HLA; Javanbakht H; Buschow SI; Woltman AM
J Virol; 2016 Jul; 90(14):6187-6199. PubMed ID: 27099316
[TBL] [Abstract][Full Text] [Related]
29. [Construction of HLA-A2-peptide tetramer and application in HBV/HCV infection].
Piao WH; He Y; Xi HL; Sun XT; Zhang HH; Xu JH; Zhao H; Xu WX; Li ZL; Wang GQ
Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(21):1818-22. PubMed ID: 15631781
[TBL] [Abstract][Full Text] [Related]
30. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells.
Larsson M; Messmer D; Somersan S; Fonteneau JF; Donahoe SM; Lee M; Dunbar PR; Cerundolo V; Julkunen I; Nixon DF; Bhardwaj N
J Immunol; 2000 Aug; 165(3):1182-90. PubMed ID: 10903715
[TBL] [Abstract][Full Text] [Related]
31. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in hepatitis B virus X antigen.
Chung MK; Yoon H; Min SS; Lee HG; Kim YJ; Lee TG; Lim JS; Kim CM; Park SN
J Immunother; 1999 Jul; 22(4):279-87. PubMed ID: 10404429
[TBL] [Abstract][Full Text] [Related]
32. Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells.
Ohta K; Yamaguchi Y; Shimizu K; Miyahara E; Toge T
Anticancer Res; 2002; 22(5):2597-606. PubMed ID: 12529970
[TBL] [Abstract][Full Text] [Related]
33. A method to increase tetramer staining efficiency of CD8+ T cells with MHC-peptide complexes: therapeutic applications in monitoring cytotoxic T lymphocyte activity during hepatitis B and C treatment.
Tsai SL; Lee TH; Chien RN; Liao SK; Lin CL; Kuo GC; Liaw YF
J Immunol Methods; 2004 Feb; 285(1):71-87. PubMed ID: 14871536
[TBL] [Abstract][Full Text] [Related]
34. The high prevalence of the I27 mutant HBcAg18-27 epitope in Chinese HBV-infected patients and its cross-reactivity with the V27 prototype epitope.
Liu HG; Chen WW; Fan ZP; Yang HY; Shi M; Zhang Z; Luan SS; Zhang H; Lu P; Tien P; Wang FS
Clin Immunol; 2007 Dec; 125(3):337-45. PubMed ID: 17900990
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer
Chen J; Guo XZ; Li HY; Zhao JJ; Xu WD
World J Gastroenterol; 2017 Feb; 23(5):817-829. PubMed ID: 28223726
[TBL] [Abstract][Full Text] [Related]
36. [Immune responses of dendritic cells after loaded with cytotoxicity T lymphocyte epitope based peptide of human alpha-fetoprotein (hAFP)].
Guo J; Cai M; Wei D; Qin L; Huang J; Wang X
Zhonghua Gan Zang Bing Za Zhi; 2002 Jun; 10(3):178-80. PubMed ID: 12113671
[TBL] [Abstract][Full Text] [Related]
37. Restoration in vitro of impaired T-cell responses in patients with chronic hepatitis B by autologous dendritic cells loaded with hepatitis B virus proteins (R2).
Duan XZ; He HX; Zhuang H
J Gastroenterol Hepatol; 2006 Jun; 21(6):970-6. PubMed ID: 16724980
[TBL] [Abstract][Full Text] [Related]
38. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
39. [Antiviral effect of human CTLs activated by HBsAg stimulated dendritic cells in vitro].
Xing LH; Wang FS; Zhu CL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Dec; 17(4):365-8. PubMed ID: 15340554
[TBL] [Abstract][Full Text] [Related]
40. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]